Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Average Recommendation of “Moderate Buy” by Analysts

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) has been assigned a consensus recommendation of “Moderate Buy” from the fourteen research firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have given a buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $44.10.

Several brokerages have recently weighed in on OLMA. Weiss Ratings restated a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research note on Tuesday, April 21st. HC Wainwright decreased their price target on Olema Pharmaceuticals from $45.00 to $38.00 and set a “buy” rating for the company in a research note on Monday, March 9th. JPMorgan Chase & Co. lifted their price target on Olema Pharmaceuticals from $55.00 to $58.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 18th. Jefferies Financial Group began coverage on Olema Pharmaceuticals in a research note on Thursday, March 19th. They issued a “buy” rating and a $40.00 price target for the company. Finally, Wolfe Research began coverage on Olema Pharmaceuticals in a research note on Friday, March 27th. They issued a “peer perform” rating for the company.

Olema Pharmaceuticals Stock Down 1.7%

Shares of Olema Pharmaceuticals stock opened at $13.59 on Friday. The business has a 50-day moving average of $15.38 and a 200-day moving average of $20.44. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.88 and a quick ratio of 9.95. The company has a market capitalization of $1.19 billion, a PE ratio of -6.73 and a beta of 2.05. Olema Pharmaceuticals has a 1-year low of $3.89 and a 1-year high of $36.26.

Olema Pharmaceuticals (NASDAQ:OLMA) last announced its earnings results on Tuesday, May 12th. The company reported ($0.52) earnings per share for the quarter, meeting the consensus estimate of ($0.52). As a group, equities analysts forecast that Olema Pharmaceuticals will post -2.19 EPS for the current fiscal year.

Insider Buying and Selling

In other Olema Pharmaceuticals news, insider Shawnte Mitchell sold 25,000 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $24.25, for a total value of $606,250.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 12.56% of the company’s stock.

Hedge Funds Weigh In On Olema Pharmaceuticals

Large investors have recently bought and sold shares of the business. EverSource Wealth Advisors LLC lifted its holdings in Olema Pharmaceuticals by 9,476.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company’s stock worth $31,000 after acquiring an additional 1,232 shares during the last quarter. Torren Management LLC bought a new position in Olema Pharmaceuticals in the fourth quarter worth about $44,000. Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new stake in shares of Olema Pharmaceuticals during the fourth quarter valued at approximately $88,000. Nisa Investment Advisors LLC raised its holdings in shares of Olema Pharmaceuticals by 14.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,764 shares of the company’s stock valued at $94,000 after buying an additional 477 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Olema Pharmaceuticals by 44.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,822 shares of the company’s stock valued at $96,000 after buying an additional 1,169 shares during the last quarter. Institutional investors own 91.78% of the company’s stock.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.